PLANTATION, Fla., Jan. 9, 2024 /PRNewswire/ -- GBI BioManufacturing, formerly known as Goodwin Biotechnology, proudly announces the signing of its second Master Supply Agreement (MSA) for commercializing a radioimmunoconjugate product. This milestone not only showcases our commitment to advancing healthcare through cutting-edge radiopharmaceuticals in collaboration with our clients, but also solidifies our position as a trusted partner in the integrated CDMO biologics space, with expertise in bringing a product from clinical trials to commercial supply.